Aurobindo Pharma’s arm to acquire 100% membership interest in Lannett Company LLC

31 Jul 2025 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc has entered into a definitive agreement with Lannett Seller Holdco, Inc under which Aurobindo Pharma USA Inc will acquire 100% of membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities. Through this acquisition, Aurobindo will gain access to a complementary portfolio of profitable products, growing Contract Development and Manufacturing Organization (CDMO) business and U.S.-based manufacturing facility with significant excess capacity (425k sq ft facility with around 3.6 billion doses capacity) and with potential for further expansion.

The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics for which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1205.95 -6.70 (-0.55%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×